Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Introduction Immunocompromised patients with B-cell depletion agents are at risk for
persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID …

Tocilizumab is an interleukin (IL)‐6 receptor inhibitor that has been proposed as a
therapeutic agent for treating coronavirus disease 2019 (COVID‐19). The aim of this …

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and …

Background Immunocompromised (IC) patients are at increased risk of severe and/or
prolonged COVID-19. Main text The recent study by Scaglione et al., addresses the issue of …

The continuing transmission of coronavirus disease 2019 (COVID-19) remains a world-wide
21st-century public health emergency of concern. Severe acute respiratory syndrome …

Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability
to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory …

Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been
responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral …

To the Editor: Convalescent plasma (CP) therapy uses neutralizing antibodies harvested
from recovered patients to treat viral infections, including severe acute respiratory syndrome …